Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “outperform” rating restated by analysts at Oppenheimer Holdings, Inc. in a research report issued on Thursday. They currently have a $83.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $75.00. Oppenheimer Holdings, Inc.’s target price would indicate a potential upside of 37.05% from the company’s current price. Oppenheimer Holdings also issued estimates for Agios Pharmaceuticals’ Q3 2017 earnings at ($1.99) EPS, Q4 2017 earnings at ($2.04) EPS, Q1 2018 earnings at ($2.31) EPS, Q2 2018 earnings at ($2.31) EPS, Q3 2018 earnings at ($2.45) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($7.28) EPS, FY2019 earnings at ($1.43) EPS and FY2020 earnings at $3.10 EPS.

Several other brokerages also recently commented on AGIO. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Needham & Company LLC boosted their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday. SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday. BidaskClub downgraded Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Janney Montgomery Scott downgraded Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $71.56.

Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down 1.35% on Thursday, hitting $59.74. The stock had a trading volume of 39,384 shares. Agios Pharmaceuticals has a 12 month low of $35.84 and a 12 month high of $67.74. The stock’s market cap is $2.88 billion. The stock has a 50 day moving average of $56.81 and a 200-day moving average of $51.69.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by $0.21. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 75.48%. The business had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. During the same quarter in the previous year, the firm earned ($1.47) earnings per share. Agios Pharmaceuticals’s revenue was up 62.1% on a year-over-year basis. Equities research analysts anticipate that Agios Pharmaceuticals will post ($6.90) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Oppenheimer Holdings, Inc. Reaffirms Outperform Rating for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/oppenheimer-holdings-inc-reaffirms-outperform-rating-for-agios-pharmaceuticals-inc-nasdaqagio/1468737.html.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total transaction of $150,060.00. Following the sale, the chief executive officer now directly owns 1,100 shares of the company’s stock, valued at $55,022. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $50.87, for a total value of $101,740.00. Following the sale, the director now directly owns 90,197 shares in the company, valued at $4,588,321.39. The disclosure for this sale can be found here. Insiders have sold 79,120 shares of company stock worth $4,557,207 over the last three months. 10.55% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of AGIO. First Trust Advisors LP boosted its stake in shares of Agios Pharmaceuticals by 17.8% in the first quarter. First Trust Advisors LP now owns 639,579 shares of the biopharmaceutical company’s stock valued at $37,351,000 after buying an additional 96,712 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Agios Pharmaceuticals by 0.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 39,473 shares of the biopharmaceutical company’s stock valued at $2,305,000 after buying an additional 126 shares during the period. C WorldWide Group Holding A S acquired a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $105,000. Canada Pension Plan Investment Board raised its position in shares of Agios Pharmaceuticals by 152.1% in the first quarter. Canada Pension Plan Investment Board now owns 30,500 shares of the biopharmaceutical company’s stock valued at $1,781,000 after buying an additional 18,400 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Agios Pharmaceuticals by 312.0% in the first quarter. Wells Fargo & Company MN now owns 40,084 shares of the biopharmaceutical company’s stock valued at $2,341,000 after buying an additional 30,354 shares during the period. 84.53% of the stock is currently owned by institutional investors.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.